Nanobiotix SA (NBTX) FinancialsNBTXFinancialNanobiotix SA

Nanobiotix SA (NBTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other Sales, accounting for 50.0% of total sales, equivalent to €5.00K. Another important revenue stream is Services. Understanding this composition is critical for investors evaluating how NBTX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Nanobiotix SA maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -590.34%, while the net margin is -144.42%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NBTX converts its operational activities into shareholder value.

In the context of the broader market, NBTX competes directly with industry leaders such as DMRA and GHRS. With a market capitalization of $2.09B, it holds a leading position in the sector. When comparing efficiency, NBTX's gross margin of 100.00% stands against DMRA's N/A and GHRS's N/A. Such benchmarking helps identify whether Nanobiotix SA is trading at a premium or discount relative to its financial performance.

Nanobiotix has shown remarkable growth with a YTD change of +86.31% and a 1-year change of +389.38%. However, the company has a negative P/E ratio of -24.92, indicating it is not currently profitable, and a high price-to-sales ratio of 70.40, which suggests it may be overvalued relative to its sales.